** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs
** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday
A HEALTHY PROGNOSIS
** J.P.Morgan ("overweight," PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis $(PBC)$ in 2025, leading to optimism about co's future
** Mizuho ("outperform," PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes
** Piper Sandler ("overweight," PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones
** RBC Capital Markets ("sector perform," PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。